as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹296.25
Change
+15.25 (5.43%)
Open
₹281.85
Prev. Close
₹281.0
Day High
₹299.7
Day Low
₹278.8
Volume Analysis
Traded
649,251
Delivered
243,252
Delivery %
37.47%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Strong operating margin (30.0%)
Weaknesses (0)
No signal for this stock
Opportunities (2)
- •Strong 3-year EPS growth (16.8%)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹325.26 | ₹312.48 | ₹304.36 | ₹291.58 | ₹283.46 | ₹270.68 | ₹262.56 |
| Fibonacci | ₹312.48 | ₹304.5 | ₹299.56 | ₹291.58 | ₹283.6 | ₹278.66 | ₹270.68 |
| Camarilla | ₹302.0 | ₹300.08 | ₹298.17 | ₹291.58 | ₹294.33 | ₹292.42 | ₹290.5 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
-2.57%
1 Week
+4.28%
1 Month
+14.4%
3 Months
-1.25%
6 Months
-21.03%
1 Year
-8.87%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹224.77
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
10.12%
Net margin 22.76% × asset turnover 0.39x × equity multiplier 1.14x
Company Overview
Sector
Healthcare
Market Cap
₹3,102 Cr
P/E (TTM)
19.1
ROE
10.5%
Book Value
₹149.0
Face Value
₹2.0
Source: Screener.in (Consolidated figures) — data as of 18 Nov 2026. Not investment advice.
TopFund Analysis
Advanced Enzyme Tech Ltd holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 65/100. The strongest factor is Financial Strength (100/100), while Momentum (21/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (30.0%). Strong 3-year EPS growth (16.8%).
TopFund Score — Fundamentals Quality
65/100 — GoodData confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company is almost debt free.
- +Company has been maintaining a healthy dividend payout of 40.9%
- −The company has delivered a poor sales growth of 8.24% over past five years.
- −Company has a low return on equity of 10.4% over last 3 years.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Transcript of earnings call held on November 03, 2026 for unaudited financial results for the quarter and half year ended September 30, 2026.
6,97,582 shares extinguished under October 2026 buyback; post-extinguishment paid-up capital falls to ₹21.91 crore.
Audio recording of Q2 and half-year FY2026 results conference call available on website.
Submitted BSE/NSE application on November 3, 2026 for promoter-group reclassification of nine members.
Newspaper publication with respect to the unaudited financial results of the Company for the quarter and six months ended September 30, 2026.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 158 | 161 | 158 | 155 | 146 | 169 | 167 | 186 | 185 | 172 | 203 | 192 | 215 |
| Expenses + | 107 | 107 | 102 | 103 | 104 | 114 | 122 | 129 | 124 | 123 | 140 | 139 | 142 |
| Operating Profit | 51 | 54 | 55 | 51 | 42 | 55 | 46 | 56 | 60 | 49 | 63 | 53 | 72 |
| OPM % | 32.0% | 33.0% | 35.0% | 33.0% | 29.0% | 33.0% | 27.0% | 30.0% | 33.0% | 29.0% | 31.0% | 28.0% | 34.0% |
| Other Income + | 6 | 14 | -6 | 7 | 10 | 8 | 9 | 9 | 10 | 20 | 7 | 11 | 9 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 9 | 9 | 9 | 9 | 9 | 9 | 10 | 10 | 10 | 10 | 10 | 10 | 11 |
| Profit before tax | 48 | 59 | 40 | 49 | 42 | 53 | 43 | 55 | 60 | 58 | 60 | 54 | 69 |
| Tax % | 27.0% | 28.0% | 25.0% | 28.0% | 21.0% | 27.0% | 38.0% | 26.0% | 25.0% | 26.0% | 24.0% | 28.0% | 26.0% |
| Net Profit + | 35 | 42 | 30 | 35 | 33 | 39 | 27 | 40 | 45 | 43 | 45 | 39 | 51 |
| EPS in Rs | 3 | 4 | 3 | 3 | 3 | 3 | 2 | 4 | 4 | 4 | 4 | 3 | 4 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | 14 | 13 | 14 | 5 | -7 | 5 | 6 | 20 | 26 | 2 | 22 | 3 | 16 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 222 | 293 | 329 | 391 | 420 | 444 | 502 | 529 | 541 | 624 | 637 | 746 | 782 |
| Expenses + | 131 | 155 | 177 | 226 | 236 | 241 | 269 | 327 | 382 | 418 | 441 | 515 | 544 |
| Operating Profit | 91 | 138 | 152 | 165 | 184 | 203 | 232 | 203 | 158 | 206 | 196 | 230 | 238 |
| OPM % | 41.0% | 47.0% | 46.0% | 42.0% | 44.0% | 46.0% | 46.0% | 38.0% | 29.0% | 33.0% | 31.0% | 31.0% | 30.0% |
| Other Income + | 1 | -3 | 3 | 1 | 5 | 6 | 9 | 6 | 21 | 21 | 33 | 46 | 47 |
| Interest | 9 | 8 | 4 | 9 | 5 | 4 | 3 | 3 | 3 | 4 | 5 | 4 | 3 |
| Depreciation | 9 | 9 | 13 | 18 | 21 | 26 | 28 | 35 | 35 | 35 | 37 | 40 | 41 |
| Profit before tax | 74 | 118 | 137 | 139 | 162 | 179 | 210 | 171 | 140 | 188 | 187 | 233 | 240 |
| Tax % | 31.0% | 35.0% | 32.0% | 33.0% | 28.0% | 26.0% | 28.0% | 28.0% | 26.0% | 27.0% | 28.0% | 25.0% | — |
| Net Profit + | 51 | 77 | 93 | 94 | 116 | 133 | 151 | 124 | 104 | 137 | 134 | 174 | 178 |
| EPS in Rs | 5 | 7 | 8 | 8 | 10 | 12 | 13 | 11 | 9 | 12 | 12 | 15 | 15 |
| Dividend Payout % | 4.0% | 3.0% | 5.0% | 6.0% | 6.0% | 5.0% | 7.0% | 9.0% | 11.0% | 43.0% | 44.0% | 36.0% | — |
| Sales growth | -7 | 32 | 12 | 19 | 7 | 6 | 13 | 5 | 2 | 15 | 2 | 17 | 11 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 188 | 256 | 442 | 537 | 657 | 817 | 948 | 1,066 | 1,213 | 1,302 | 1,398 | 1,610 | 1,643 |
| Borrowings + | 115 | 101 | 54 | 67 | 35 | 28 | 23 | 35 | 34 | 47 | 39 | 32 | 54 |
| Other Liabilities + | 92 | 71 | 65 | 102 | 91 | 104 | 153 | 137 | 142 | 150 | 151 | 170 | 187 |
| Total Liabilities | 417 | 450 | 583 | 727 | 805 | 971 | 1,146 | 1,260 | 1,411 | 1,521 | 1,611 | 1,834 | 1,906 |
| Fixed Assets + | 287 | 285 | 421 | 491 | 495 | 563 | 601 | 619 | 649 | 650 | 679 | 692 | 724 |
| CWIP | 5 | 7 | 8 | 11 | 10 | 10 | 10 | 15 | 22 | 41 | 22 | 51 | 83 |
| Investments | 0 | 0 | 0 | 0 | 111 | 124 | 121 | 102 | 360 | 403 | 480 | 584 | 488 |
| Other Assets + | 125 | 158 | 153 | 226 | 188 | 275 | 413 | 524 | 380 | 427 | 430 | 507 | 610 |
| Total Assets | 417 | 450 | 583 | 727 | 805 | 971 | 1,146 | 1,260 | 1,411 | 1,521 | 1,611 | 1,834 | 1,906 |
| Equity Capital | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 54 | 93 | 107 | 116 | 129 | 141 | 163 | 122 | 140 | 141 | 142 | 157 |
| Cash from Investing Activity + | -15 | -10 | -60 | -60 | -124 | -43 | -27 | 2 | -286 | -65 | -89 | -72 |
| Cash from Financing Activity + | -36 | -63 | -65 | -2 | -43 | -39 | -26 | -48 | -26 | -59 | -73 | -70 |
| Net Cash Flow | 2 | 21 | -18 | 54 | -38 | 60 | 109 | 75 | -171 | 17 | -20 | 15 |
| Free Cash Flow | 42 | 88 | 97 | 105 | 116 | 90 | 143 | 95 | 102 | 94 | 108 | 105 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 88 | 88 | 105 | 97 | 70 | 94 | 94 | 87 | 112 | 93 | 103 | 96 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 26.88% | 25.95% | 36.87% | 36.4% | 36.31% | 36.82% | 25.0% | 25.09% | 25.62% | 25.85% | 25.28% | 27.9% |
| Promoters | 43.62% | 43.5% | 43.02% | 42.95% | 42.92% | 43.08% | 43.08% | 43.08% | 43.04% | 43.26% | 43.25% | 43.56% |
| FII | 22.54% | 23.01% | 12.03% | 12.63% | 12.57% | 11.9% | 23.45% | 25.41% | 25.85% | 25.5% | 26.7% | 26.64% |
| DII | 6.98% | 7.56% | 8.08% | 8.02% | 8.17% | 8.19% | 8.45% | 6.41% | 5.51% | 5.41% | 4.77% | 1.89% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Advanced Enzyme Tech Ltd (this stock) | 3,102 | 19.1 | 1.9 | 10.5% |
| Ind Swift Laboratories Lt | 2,881 | 31.4 | 1.95 | 4.02% |
| Solara Active Pha Sci Ltd | 3,347 | 70.7 | 2.33 | -0.13% |
| Unichem Laboratories Ltd | 3,511 | 29.5 | 1.26 | 3.17% |
| Hikal Limited | 2,690 | 37.8 | 2.28 | 2.21% |
| Shukra Pharmaceuticals L | 3,639 | 82.1 | 30.56 | 28.9% |
| Fredun Pharmaceuticals L | 2,548 | 48.1 | 7.59 | 15.6% |
Which Mutual Funds Hold Advanced Enzyme Tech Ltd?
Frequently Asked Questions about Advanced Enzyme Tech Ltd
Advanced Enzyme Tech Ltd (ADVENZYMES) closed at ₹296.25 on NSE on 19 November 2026, up 15.25 (5.43%) from the previous close.
Advanced Enzyme Tech Ltd trades on the NSE (National Stock Exchange of India) under the symbol ADVENZYMES.
Advanced Enzyme Tech Ltd has a trailing twelve-month P/E (price-to-earnings) ratio of 19.1.
Advanced Enzyme Tech Ltd has a dividend yield of 1.89%.
Advanced Enzyme Tech Ltd's 52-week high is ₹420.0 and its 52-week low is ₹247.0.
Advanced Enzyme Tech Ltd has a market capitalisation of ₹3,102 crore.
Advanced Enzyme Tech Ltd has a TopFund Quality Score of 65/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Advanced Enzyme Tech Ltd?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.